The World Health Organization (WHO) has proposed that antimicrobial resistance is one of the greatest threats to global public health in the 21st century. This crisis has revived interest in bacteriophages, viruses that specifically infect bacteria, as a potential solution. Phage therapy offers distinct advantages as a precision antimicrobial, with high efficacy rates, excellent safety profiles, high specificity, and low dose requirements.
However, their use in modern medicine has been limited by the challenge of finding, isolating, and engineering effective strains. Their high specificity, while advantageous for avoiding off-target effects, can also constrain clinical utility, as many phages infect only narrow subsets of bacterial strains.
“In the early 20th century, phage therapies were explored in parallel with antibiotic therapy. But once commercially relevant antibiotics emerged, particularly broad-spectrum antibiotics, Western medicine standardized around drugs that were easy to mass-produce, were cost effective, and fit cleanly into frameworks for clinical trials and regulation,” Tiffany Vora, Fellow at Singularity University, told DDN. “In contrast, phage therapy is by its nature specific and dynamic, making it harder to fit phage therapies into standard therapeutic business models.”
Today, the alarming rise of antibiotic resistance around the world, the resurgence of diseases that were previously treatable, and powerful new advances in biological engineering and manufacturing all motivate a fresh look at the utility of phage therapies.
—Tiffany Vora, Singularity University
On top of this, phages have historically been more complex to source, manufacture, quality-control, and distribute than conventional antibiotics. “Today, the alarming rise of antibiotic resistance around the world, the resurgence of diseases that were previously treatable, and powerful new advances in biological engineering and manufacturing all motivate a fresh look at the utility of phage therapies,” said Vora.
One of the most promising approaches to broaden the host range of phages and enhance their effectiveness is through phage engineering. Now, researchers from New England Biolabs (NEB) and Yale University have announced a breakthrough that could transform the field. In a new study published in PNAS, they describe the first fully synthetic bacteriophage engineering system for Pseudomonas aeruginosa, one of the most clinically challenging antibiotic-resistant pathogens.
How does it work?
The study builds on prior work from NEB’s lab, which in November 2025 validated the High-Complexity Golden Gate Assembly (HC-GGA) platform for phage genome synthesis. The method works by removing internal restriction sites from the target genome and splitting it into dozens of short fragments (2–5kb). Each fragment is flanked by unique overhangs, enabling a single “one-pot” reaction to assemble the full genome in correct order. The resulting synthetic genome can then be transformed into a host bacterium to produce viable phages.
This means that instead of isolating phages from the environment and then painstakingly modifying them in bacterial hosts, scientists can now design phage genomes digitally, assemble them in the lab, and introduce them into safe host strains for testing.
“Historically, phage work has often started with environmental sampling (literally fishing phages out of sewage or soil) and then spending months to years characterizing, adapting, and re-engineering what nature happened to provide. That approach works, but it’s slow and hard to scale or standardize,” said Vora.
The new synthetic method, by contrast, is designed for speed and scalability — and it doesn’t require specialized bacterial strains or iterative in-cell editing.
A customizable phage therapy
The team demonstrated the system by assembling a P. aeruginosa phage from 28 synthetic DNA fragments. They then programmed the phage with new behaviors, including swapping tail fiber genes to alter host range and inserting fluorescent reporters to visualize infection in real time. These modifications show that phage genomes can be treated like modular, programmable systems.
“We introduced point mutations, gene swaps, insertions, deletions, and functional gene additions — often combining multiple changes simultaneously,” Greg Lohman, Senior Principal Investigator at NEB and co-author of the study, told DDN.
Golden Gate Assembly is particularly well-suited to this approach because it joins many short DNA fragments in a single reaction. This reduces toxicity to host cells, improves accuracy, and is less sensitive to the repeats and extreme GC content often found in phage genomes. In practical terms, it means researchers can assemble complex phage genomes more reliably and with fewer errors.
“Engineering phages offers a path toward pre-manufactured, well-defined therapeutics that may be easier to manufacture and navigate through regulatory approval, but they will remain much more personalized (bacteria-specific) than antibiotics,” said Lohman. “Phages can be designed to be strictly lytic, to broaden host range, or to form defined libraries optimized for coverage and resistance mitigation.”
Lohman also stated that in the near term, easier engineering will also accelerate fundamental understanding of phage biology, host interactions, resistance mechanisms, and safety considerations.
Why this matters for phage therapy
The implications for therapeutic development could be profound.
This represents a methodological breakthrough that will substantially accelerate phage therapy development, from basic biology to therapeutic screening, efficacy testing, and safety assessment.
—Greg Lohman, New England Biolabs
Antibiotic-resistant infections are a growing public health crisis, and phage therapy has long been viewed as one of the most promising alternatives. But without a scalable engineering platform, phage therapy has struggled to move beyond individual case studies. A synthetic phage engineering system changes that by enabling the creation of phage libraries, rapid iteration, and precise customization for specific pathogens and clinical contexts.
“This represents a methodological breakthrough that will substantially accelerate phage therapy development, from basic biology to therapeutic screening, efficacy testing, and safety assessment,” said Lohman.
This breakthrough also signals a broader shift in how we think about biological therapeutics. Just as synthetic biology has transformed plant and microbial engineering, it may now be poised to transform bacteriophage therapy — turning phages from natural curiosities into programmable drugs.
“Hopefully, this work will democratize access by opening the door to more “drag-and-drop” style engineering, empowering many more labs to innovate, test, and deliver safe and effective therapies,” said Vora.
However, plenty of challenges still remain, including regulatory hurdles, immune response considerations, and the potential for bacterial resistance to phages.
“Routine phage use for acute disease requires rapid diagnostics to identify the causative bacterium and its susceptibility, manufacturing pipelines that can consistently produce high-quality phage preparations, and clinical workflows that can accommodate precision matching rather than off-the-shelf prescribing. Without those pieces in place, even effective phages may remain difficult to deploy at scale,” noted Vora.
Despite this, advances in diagnostics, synthetic biology, manufacturing, and more flexible regulatory thinking are converging. What was once a fragmented and artisanal approach to phage therapy is now beginning to resemble a coherent, scalable technological platform.
In the fight against antibiotic resistance, the ability to design, build, and deploy synthetic phages could be one of the most important innovations of the decade — a major step toward a future where bacteria are no longer able to outpace human medicine.
